Hudson Executive Capital LP 13D and 13G filings for Akoya Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-07 4:30 pm Sale | 2023-02-03 | 13D | Akoya Biosciences, Inc. AKYA | Hudson Executive Capital LP | 1,892,204 4.990% | -555,354 (-22.69%) | Filing |
| 2022-12-02 4:15 pm Sale | 2022-11-30 | 13D | Akoya Biosciences, Inc. AKYA | Hudson Executive Capital LP | 2,447,558 6.400% | -1,250,000 (-33.81%) | Filing |
| 2022-09-13 4:10 pm Purchase | 2022-09-09 | 13D | Akoya Biosciences, Inc. AKYA | Hudson Executive Capital LP | 3,697,558 9.800% | 1,617,015 (+77.72%) | Filing |
| 2021-10-18 4:02 pm Purchase | 2021-10-06 | 13D | Akoya Biosciences, Inc. AKYA | Hudson Executive Capital LP | 2,080,543 5.600% | 2,080,543 (New Position) | Filing |